Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Vidal

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
British Journal of Cancer|November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II studyFlorence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
The Lancet Regional Health. Europe|July 7, 2023
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trialMarc Sapoval, Nicolas Thiounn, Aurélien Descazeaud, et al.
The Lancet. Oncology|November 7, 2017
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialValérie Vilgrain, Helena Pereira, Eric Assenat, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
British Journal of Cancer|November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II studyFlorence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
The Lancet Regional Health. Europe|July 7, 2023
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trialMarc Sapoval, Nicolas Thiounn, Aurélien Descazeaud, et al.
The Lancet. Oncology|November 7, 2017
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialValérie Vilgrain, Helena Pereira, Eric Assenat, et al.
Pageof 10